Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.59 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677599 | 0.98 | RARB (0.71) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL18314362 | 0.98 | RARB (0.71) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL7909288 | 0.97 | RARB (0.63) | RARBTP53TSHRPLA2G4BL3MBTL1 | |
| SCHEMBL19130182 | 0.95 | TP53 (0.66) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL19130711 | 0.94 | TP53 (0.69) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL13385664 | 0.94 | TP53 (0.69) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL19130183 | 0.94 | TP53 (0.69) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL9378715 | 0.92 | TSHR (0.60) | RARBTP53TSHRPLA2G4BL3MBTL1 | |
| SCHEMBL10746659 | 0.87 | RARB (0.68) | RARBTP53TSHRPLA2G4BPLA2G4A | |
| SCHEMBL9327561 | 0.87 | RARB (0.68) | RARBTP53TSHRPLA2G4BPLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20120190613-A1 | ECHINOCANDIN DERIVATIVES | JAMES JR KENNETH DUKE (US) | 2012-07-26 | — | — | US | disclosed |
| US-7902148-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2011025875-A1 | ECHINOCANDIN DERIVATIVES | SEACHAID PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20090221470-A1 | USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT | CUMBERLAND PHARMACEUTICALS INC. | 2009-09-03 | — | — | US | disclosed |
| US-7452861-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | LIPA, LIPG, LIPC | RARB 2288/4885TP53 4436/4885TSHR 2690/4885 |
| US-20120190613-A1 | ECHINOCANDIN DERIVATIVES | ERG28, DPM1, EML4 | RARB 4179/4885TP53 1662/4885TSHR 4636/4885 |
| US-20090221470-A1 | USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT | DPM1, ERG28, ENGASE | RARB 4821/4885TP53 2761/4885TSHR 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.